Ovarian Cancer Drugs Market Size in 7MM is expected to grow at a decent CAGR by 2034, estimates DelveInsight

DelveInsight's "Ovarian Cancer Market Insight, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of high- and low-grade serous ovarian cancer, its historical and forecasted epidemiology, and the market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Discover which therapies are expected to grab the Ovarian Cancer Drugs Market Share @ Ovarian Cancer Market Outlook- https://www.delveinsight.com/sample-request/ovarian-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Ovarian Cancer Drugs Market Report
• In May 2025, Theolytics Limited announced a clinical trial is to establish if THEO-260 is safe to administer to adult females with ovarian cancer. It will also aim to establish if THEO-260 is able to treat ovarian cancer.
• In May 2025, Daiichi Sankyo announced a clinical trial is designed to evaluate the efficacy and safety of T-DXd in combination with bevacizumab versus bevacizumab monotherapy as first-line maintenance therapy, in participants with human epidermal growth factor 2 (HER2)-expressing (immunohistochemistry [IHC] 3+/2+/1+) advanced high-grade epithelial ovarian cancer.
• In May 2025, Tesaro Inc. organized a study will evaluate the efficacy and safety of niraparib and novel treatment combinations of niraparib as described within each cohort-specific supplement in participants with ovarian, fallopian tube, or primary peritoneal cancer. Cohort A (single arm) includes participants with recurrent ovarian cancer. Cohort B will not be initiated. Cohort C (randomized-2 arms) includes participants with newly diagnosed ovarian cancer.
• In May 2025, Lipomedix Pharmaceuticals Inc. announced a Phase 2a study was designed to evaluate the safety, tolerability, and efficacy of Promitil in patients with recurrent ovarian cancer and inoperable, locally advanced or metastatic pancreatic cancer, which bears deleterious germline or somatic mutations in BRCA1, BRCA2, or HRD (homologous recombination deficiency) -related genes.
• In the 7MM, the US accounted for the highest number of incident cases of High- and low-grade serous ovarian Cancer. In the 7MM, there were nearly 37,600 cases in 2024.
• Among EU4 and the UK, the UK had the highest number of cases of LGSOC, followed by Germany, whereas Spain was at the bottom of the ladder.
• The number of incident cases of HRD (gLOH = 16%) was much higher in HGSOC than in MAPK (BRAF/KRAS/NRAS/NF1). MAPK cases are predominant in LGSOC. In the US, in 2024, the HRD cases accounted for nearly 5,160.
• Data suggest that in LGSOC, the majority of cases have Stage III disease at diagnosis. About 70-80% of people are diagnosed with Stage III, and about 10% of people are diagnosed with Stage IV. In Japan, LGSOC early-stage and advanced-stage were around 30 and 325, respectively, in 2024.
• The leading Ovarian Cancer Companies such as Genmab, AstraZeneca, On Target Laboratories, Chipscreen Biosciences, Aravive, Inc., Allarity Therapeutics, Merck KGaA, GlaxoSmithKline, Aprea Therapeutics, Verastem, Inc., Ellipses Pharma, Impact Therapeutics, Inc., BeiGene, Apexigen, Novartis Oncology, VBL Therapeutics., Cristal Therapeutics, Bayer, Regeneron Pharmaceuticals, DCPrime BV, AIM ImmunoTech Inc., Pharmicell Co., Ltd., Shattuck Labs, Inc., Laekna Limited, Celsion, and others.
• Promising Ovarian Cancer Pipeline Therapies such as Tisotumab Vedotin, Pembrolizumab, Adavosertib, AVB-500, and Others.

Stay ahead in the Ovarian Cancer Drugs Market with DelveInsight's Strategic Report @ Ovarian Cancer Market Outlook- https://www.delveinsight.com/sample-request/ovarian-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Ovarian Cancer Epidemiology Segmentation in the 7MM
• Total Ovarian Cancer Incident cases
• Ovarian Cancer Age-specific cases
• Ovarian Cancer Type-specific Cases
• Stage-specific Cases of High- and Low-Grade Serous Ovarian Cancer
• Biomarker-specific Cases of High- and Low-Grade Serous Ovarian Cancer

Download the report to understand which factors are driving Ovarian Cancer Epidemiology trends @ Ovarian Cancer Prevalence- https://www.delveinsight.com/sample-request/ovarian-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Ovarian Cancer Marketed Drugs
• RUBRACA (rucaparib): pharma& GmbH
RUBRACA is an oral, small-molecule inhibitor of Poly (ADP-ribose) Polymerase (PARP) 1, 2, and 3 that is being developed in multiple tumor types, including ovarian and prostate cancers, as monotherapy and in combination with other anti-cancer agents. Currently, it is approved for the maintenance treatment of adult patients with recurrent Epithelial Ovarian Carcinoma (EOC), Fallopian Tube Carcinoma (FTC), or Primary Peritoneal Cancer (PPC) who are in complete response (CR) or partial response (PR) to platinum-based chemotherapy. It was granted the first US FDA approval in 2016 for the treatment of patients with deleterious BRCA mutation (germline and/or somatic) associated with advanced ovarian cancer. In November 2023, the European Commission granted marketing authorization for a Type II variation for RUBRACA as a first-line maintenance treatment for all women with advanced ovarian cancer, regardless of their BRCA mutation status, who have responded to first-line platinum-based chemotherapy.

• ZEJULA (niraparib): GlaxoSmithKline
Niraparib is an oral potent, highly selective PARP1 and PARP2 inhibitor. PARP is a protein that plays a fundamental role in detecting and repairing DNA damage in cells, including damage induced by chemotherapy. Niraparib is a PARP inhibitor; it works by inhibiting the repair of damaged DNA and inducing cell death. In March 2017, the US FDA approved ZEJULA for the maintenance treatment (intended to delay cancer growth) of adult patients with recurrent EOC, FTC, or PPC, whose tumors have completely or partially shrunk (CR or PR), respectively, in response to platinum-based chemotherapy. In 2020, the FDA approved ZEJULA for the maintenance treatment of adult patients with advanced EOC, FTC, or PPC who are in CR or PR to first-line platinum-based chemotherapy.

Ovarian Cancer Emerging Drugs
• Avutometinib (VS-6766) + Defactinib (VS-6063): Verastem Oncology
Avutometinib is an RAF/MEK Clamp that induces inactive complexes of MEK with ARAF, BRAF, and CRAF, potentially creating a more complete and durable antitumor response through maximal RAS pathway inhibition. Avutometinib blocks both RAF and MEK in a single molecule, suggesting it may help overcome resistance and ultimately block tumor growth and proliferation.

• Raludotatug deruxtecan: Daiichi Sankyo
Raludotatug deruxtecan (R-DXd) is an investigational, potential first-in-class CDH6-directed ADC. Designed using Daiichi Sankyo's proprietary DXd ADC Technology, raludotatug deruxtecan is comprised of a humanized anti-CDH6 IgG1 monoclonal antibody attached to a number of topoisomerase I inhibitor payloads (an exatecan derivative, DXd) via tetrapeptide-based cleavable linkers.

To learn more about Ovarian Cancer Treatment guidelines, visit @ Ovarian Cancer Treatment Market Landscape- https://www.delveinsight.com/sample-request/ovarian-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Ovarian Cancer Companies
Genmab, AstraZeneca, On Target Laboratories, Chipscreen Biosciences, Aravive, Inc., Allarity Therapeutics, Merck KGaA, GlaxoSmithKline, Aprea Therapeutics, Verastem, Inc., Ellipses Pharma, Impact Therapeutics, Inc., BeiGene, Apexigen, Novartis Oncology, VBL Therapeutics., Cristal Therapeutics, Bayer, Regeneron Pharmaceuticals, DCPrime BV, AIM ImmunoTech Inc., Pharmicell Co., Ltd., Shattuck Labs, Inc., Laekna Limited, Celsion, and others.

Ovarian Cancer Market Outlook
Ovarian cancer treatment typically involves a combination of surgery, chemotherapy, and targeted therapy. Surgery aims to remove cancerous tissue, while chemotherapy, administered orally or intravenously, works to shrink or destroy cancer cells. Targeted therapy blocks cancer growth and spread and is used when specific tests confirm its suitability. HGSOC, the most common type, is usually treated with surgery and chemotherapy. Patients with early-stage disease often undergo surgery first, followed by approximately six rounds of chemotherapy. Those with advanced disease may begin with chemotherapy to shrink tumors before surgery, followed by additional chemotherapy afterward. A patient's BRCA (breast cancer gene) or HRD (homologous recombination deficiency) status does not alter initial chemotherapy but influences maintenance therapy. Patients with BRCA or HRD mutations often benefit from PARP inhibitors, a type of oral targeted therapy designed to prevent recurrence. Ongoing clinical trials are evaluating new treatment options. Radiation therapy, including intraperitoneal radiation, is being studied for advanced cases. Immunotherapy is being explored to strengthen the body's natural ability to fight cancer, while vaccine therapy is being developed to train the immune system to recognize and attack cancer cells more effectively.

Learn more about the FDA-approved drugs for Ovarian Cancer @ Drugs for Ovarian Cancer Treatment- https://www.delveinsight.com/sample-request/ovarian-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Ovarian Cancer Market Report
• Coverage- 7MM
• Study Period- 2020-2034
• Ovarian Cancer Companies- Genmab, AstraZeneca, On Target Laboratories, Chipscreen Biosciences, Aravive, Inc., Allarity Therapeutics, Merck KGaA, GlaxoSmithKline, Aprea Therapeutics, Verastem, Inc., Ellipses Pharma, Impact Therapeutics, Inc., BeiGene, Apexigen, Novartis Oncology, VBL Therapeutics., Cristal Therapeutics, Bayer, Regeneron Pharmaceuticals, DCPrime BV, AIM ImmunoTech Inc., Pharmicell Co., Ltd., Shattuck Labs, Inc., Laekna Limited, Celsion, and others.
• Ovarian Cancer Pipeline Therapies- Tisotumab Vedotin, Pembrolizumab, Adavosertib, AVB-500, and Others.
• Ovarian Cancer Market Dynamics: Ovarian Cancer Market Drivers and Barriers
• Ovarian Cancer Market Access and Reimbursement, Unmet Needs and Future Perspectives

Discover more about Ovarian Cancer Drugs in development @ Ovarian Cancer Clinical Trials Assessment- https://www.delveinsight.com/sample-request/ovarian-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Contents
1. KEY INSIGHTS
2. REPORT INTRODUCTION
3. EXECUTIVE SUMMARY
4. KEY EVENTS
5. EPIDEMIOLOGY AND MARKET FORECAST METHODOLOGY
6. HIGH-GRADE AND LOW-GRADE SEROUS OVARIAN CANCER MARKET OVERVIEW AT A GLANCE IN THE 7MM
7. DISEASE BACKGROUND AND OVERVIEW
8. EPIDEMIOLOGY AND PATIENT POPULATION OF 7MM
9. PATIENT JOURNEY
10. MARKETED DRUGS
11. EMERGING DRUGS
12. HIGH- AND LOW-GRADE SEROUS OVARIAN CANCER: 7MM
13. Unmet Needs
14. SWOT Analysis
15. KOL Views
16. Market Access and Reimbursement
17. APPENDIX
18. DELVEINSIGHT CAPABILITIES
19. DISCLAIMER
20. ABOUT DELVEINSIGHT

List of Top Selling Market Research Reports in 2025

CAR-T Pipeline- https://www.delveinsight.com/report-store/car-t-pipeline-insight
Cystic Fibrosis Market- https://www.delveinsight.com/report-store/cystic-fibrosis-market
Indwelling Catheters Market- https://www.delveinsight.com/report-store/urinary-catheters-market
Ly3454738 Drug Insight- https://www.delveinsight.com/report-store/moderate-to-severe-atopic-dermatitis-pipeline-insight
NK Cell Therapy Market- https://www.delveinsight.com/report-store/nk-cell-therapy-market
Periodontal Disease Market- https://www.delveinsight.com/report-store/periodontal-disease-market
Scoliosis Market- https://www.delveinsight.com/report-store/scoliosis-market
Urea Cycle Disorders Market- https://www.delveinsight.com/report-store/urea-cycle-disorders-pipeline-insight
Attention Deficit Hyperactivity Disorder Market- https://www.delveinsight.com/report-store/attention-deficit-hyperactivity-disorder-adhd-market
Cardiac Implantable Electronic Devices Market- https://www.delveinsight.com/report-store/cardiac-implantable-electronic-devices-cieds-market
Positive Airway Pressure Device Market- https://www.delveinsight.com/report-store/positive-airway-pressure-device-market
Surgical Energy Instruments Market- https://www.delveinsight.com/report-store/surgical-energy-instruments-electrosurgical-devices-market
Stem Cell Market- https://www.delveinsight.com/report-store/stem-cell-market
Thrombectomy Devices Market- https://www.delveinsight.com/report-store/thrombectomy-devices-market
Cardiac Monitoring Devices Market- https://www.delveinsight.com/report-store/cardiac-monitoring-devices-market
Hip Replacement Devices Market- https://www.delveinsight.com/report-store/hip-reconstruction-devices-market
Medical Marijuana Market- https://www.delveinsight.com/report-store/medical-marijuana-market
Total Knee Arthroplasty Market- https://www.delveinsight.com/report-store/knee-reconstruction-devices-market
Healthcare Competitive Benchmarking- https://www.delveinsight.com/consulting/competitive-benchmarking-services
Lice Infestations Market- https://www.delveinsight.com/report-store/lice-infestations-pipeline-insight
Lactose Intolerance Market- https://www.delveinsight.com/report-store/lactose-intolerance-market
Antibody Drug Conjugate Market- https://www.delveinsight.com/report-store/antibody-drug-conjugate-adc-market
Sepsis Market- https://www.delveinsight.com/report-store/sepsis-market-insight
Surgical Mask & Respirator Market- https://www.delveinsight.com/report-store/surgical-mask-respirator-market

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: +91-9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.